This study is testing a new oral medication called VNT-101 for influenza (the flu). VNT-101 works by stopping the influenza virus from making more copies of itself. Researchers want to learn about the safety of VNT-101, how well your body tolerates it, and how it moves through your body. The study will involve about 78 healthy adults between 18 and 59 years old. Participants will receive either VNT-101 or a placebo (an inactive pill). The main goal is to see if VNT-101 causes any changes in your heart readings (ECG), lab tests, or vital signs (like blood pressure or heart rate) over 13 days. The current status of this study is unclear.

Study design

This is a Phase 1, randomized, double-blind, placebo-controlled study involving about 78 healthy adults. It has two parts: one testing single doses and another testing multiple doses of VNT-101.

What's involved

You would need to provide written informed consent, be available for all study visits, and comply with all planned trial procedures. The study measures changes from baseline in ECG, lab parameters, and vital signs from Day 1 through Day 13.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoints are measured from Day 1 through Day 13, indicating a follow-up period of at least 13 days after the start of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.